Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1778-1786

  Kim, Wook Youn ^a,b   Nam, Soo Jeong ^b,c   Kim, Sehui ^b,c   Kim, Tae Min ^c   Heo, Dae Seog ^c   Kim, Chul Woo ^b,c   Jeon, Yoon Kyung ^b,c  

^a Konkuk University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Brentuximab vedotin; CD30; EBV; Extranodal NK T cell lymphoma; Non Anthracycline based chemotherapy; Prognosis

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NK T CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT FAILURE; TREATMENT RESPONSE; ADOLESCENT; AGED; BIOSYNTHESIS; CHILD; DISEASE FREE SURVIVAL; DRUG THERAPY; KAPLAN MEIER METHOD; LYMPHOMA, EXTRANODAL NK-T-CELL; METABOLISM; MIDDLE AGED; NATURAL KILLER T CELL; PATHOLOGY; PROCEDURES; PROGNOSIS; REMISSION; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD30; CHEMORADIOTHERAPY; CHILD; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84932122437     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.974048     Document Type: Article

References (36)

1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp 285-288.
2. Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: A national survey of the Korean Cancer Study Group. Ann Oncol 2008; 19: 1477-1484.
3. Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci 2009; 100: 2242-2248.
4. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 1402-1408.
5. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/ II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 3785-3790.
6. Lee J, Suh C, Park Y H, et al. E xtranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618.
7. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216-221.
8. Lee K W, Yun T, Kim D W, et al. F irst-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy/radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 2006; 47: 1274-1282.
9. Kim BS, Kim TY, Kim CW, et al. Th erapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy-result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 2003; 42: 779-783.
10. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L- Asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 1016-1020.
11. Deutsch Y E, Tadmor T, Podack E R, et al. C D30: An important new target in hematologic malignancies. Leuk Lymphoma 2011; 52: 1641-1654.
12. Hu S, Xu-Monette Z Y, Balasubramanyam A, et al. C D30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121: 2715-2724.
13. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.
14. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/ refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012; 18: 248-255.
15. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190-2196.
16. Chen R, Palmer JM, Th omas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012; 119: 6379-6381.
17. Gaal K, Sun NC, Hernandez AM, et al. Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol 2000; 24: 1511-1517.
18. Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al. Natural killer/ natural killer-like T-cell lymphoma, CD56 , presenting in the skin: An increasingly recognized entity with an aggressive course. J Clin Oncol 2001; 19: 2179-2188.
19. Kuo TT, Shih LY, Tsang NM. Nasal NK/T cell lymphoma in Taiwan: A clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol 2004; 12: 375-387.
20. Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000; 89: 2106-2116.
21. Li T, Zhang B, Ye Y, et al. Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas. Hum Pathol 2006; 37: 54-60.
22. Lu D, Lin C N, Chuang S S, et al. T-cell and NK/T-cell lymphomas in southern Taiwan: A study of 72 cases in a single institute. Leuk Lymphoma 2004; 45: 923-928.
23. Schwartz EJ, Molina-Kirsch H, Zhao S, et al. Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: An analysis of 84 cases. Am J Clin Pathol 2008; 130: 343-351.
24. Hong J, Park S, Baek H L, et al. T umor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol 2012; 5: 939-947.
25. Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica 2013; 98: e81-e82.
26. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16: 888-897.
27. Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Th er Adv Hematol 2012; 3: 209-225.
28. Savage KJ, Harris NL, Vose JM, et al. ALK- Anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-5504.
29. Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience. Ann Oncol 2006; 17: 123-130.
30. Bisig B, de Reynies A, Bonnet C, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica 2013; 98: 1250-1258.
31. Kanemitsu N, Isobe Y, Masuda A, et al. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and-negative ENKL. Clin Cancer Res 2012; 18: 2164-2172.
32. Liu X, Wang B, Ma X, et al. N F-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type. Jpn J Clin Oncol 2009; 39: 418-424.
33. Hsu PL, Hsu SM. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin ' s disease and anaplastic large cell lymphoma. Lab Invest 2000; 80: 1111-1119.
34. Muta H, Boise LH, Fang L, et al. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol 2000; 165: 5105-5111.
35. Paik J H, Jeon Y K, Go H, et al. E xtranodal NK/T cell lymphoma accompanied by heavy eosinophilic infiltration and peripheral blood eosinophilia, involving skeletal muscles. Korean J Pathol 2011; 45: S70-S74.
36. Min HS, Hyun CL, Paik JH, et al. An autopsy case of aggressive CD30 extra-nodal NK/T-cell lymphoma initially manifested with granulomatous myositis. Leuk Lymphoma 2006; 47: 347-352.